Literature DB >> 10329846

IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level.

K Miyazawa1, A Mori, H Okudaira.   

Abstract

BACKGROUND: Involvement of IL-6 in the pathogenesis of rheumatoid arthritis has recently been demonstrated, but the mechanism of its production by rheumatoid synoviocytes is still poorly defined.
OBJECTIVE: The purpose of this study was to clarify the cellular and molecular mechanisms involved in the spontaneous production of IL-6 by fibroblast-like synoviocytes obtained from patients with rheumatoid arthritis.
METHODS: Cloned synoviocytes were established by the limiting dilution method. IL-6 synthesis was evaluated by ELISA and Northern blot analysis. IL-6 gene transcription and transcription factors were analyzed by the transient transfection of luciferase reporter plasmids and the electrophoretic mobility shift assay, respectively.
RESULTS: IL-6 synthesis by cloned rheumatoid synoviocytes was spontaneously upregulated at the transcriptional level. Enhanced IL-6 production by high-producing clones was independent of cytokines from other cell populations or autocrine production of tumor necrosis factor-alpha and IL-1. Deletion analysis showed that the IL-6 promoter was regulated by 2 positive elements (-159 to -142 base pair and -77 to -59 base pair). The transcriptional activity of the latter element was upregulated in clones showing high IL-6 production. The binding activity of NF-kappaB p50/p65 heterodimer and RBP-Jkappa was enhanced in these clones.
CONCLUSION: IL-6 production by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level and spontaneous activation of NF-kappaB and RBP-Jkappa seems to be involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329846     DOI: 10.1016/s0091-6749(99)70159-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice.

Authors:  Eun Young Lee; Chang-Keun Lee; Ki-Up Lee; Joong Yeol Park; Kyung-Ja Cho; You Sook Cho; Hee Ran Lee; Se Hwan Moon; Hee-Bom Moon; Bin Yoo
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

3.  Expression and function of wingless and frizzled homologs in rheumatoid arthritis.

Authors:  M Sen; K Lauterbach; H El-Gabalawy; G S Firestein; M Corr; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  IL-6 blocks a discrete early step in lymphopoiesis.

Authors:  Kazuhiko Maeda; Yoshihiro Baba; Yoshinori Nagai; Kozo Miyazaki; Alexander Malykhin; Koji Nakamura; Paul W Kincade; Nobuo Sakaguchi; K Mark Coggeshall
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

5.  Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation.

Authors:  Joanna Stanczyk; Caroline Ospelt; Emmanuel Karouzakis; Andrew Filer; Karim Raza; Christoph Kolling; Renate Gay; Christopher D Buckley; Paul P Tak; Steffen Gay; Diego Kyburz
Journal:  Arthritis Rheum       Date:  2011-02

6.  All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation.

Authors:  Mélanie Kirchmeyer; Meriem Koufany; Sylvie Sebillaud; Patrick Netter; Jean-Yves Jouzeau; Arnaud Bianchi
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

7.  Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow.

Authors:  Koji Nakamura; Taku Kouro; Paul W Kincade; Alexander Malykhin; Kazuhiko Maeda; K Mark Coggeshall
Journal:  J Exp Med       Date:  2004-01-12       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.